Regeneron Pharmaceuticals Inc

REGN 
(NASDAQ) 
 
$ 312.55 <%= Resources.Global.txtDown %>
Updated 23/06/2019
Change % -2.41% Stock price decreasing
Change -7.71 Stock price decreasing
Volume 523,316
High $ 320.28
Low $ 311.37
Open $ 318.76
ISIN
Prev close $ 320.26
# of shares 107.73M
Market cap 33,670M USD
Intraday

Market closed
Regeneron Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  312.55 1.9% Stock price increasing 0.0% Stock price decreasing -20.9% Stock price decreasing -8.2% Stock price decreasing -4.5% Stock price decreasing
Powered by TradingView

News about Regeneron Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2019 03:27:55
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-25 04:27:55 - 2019-06-25 03:27:55 - 1000 - Website: OKAY